类胚胎致死性异常视觉基因1表达与卵巢浆液性癌化疗耐药及预后关系研究

发布时间：2018-07-06 16:54

本文选题：卵巢浆液性癌 + 类胚胎致死性异常视觉基因　；参考：《中国实用妇科与产科杂志》2016年03期

【摘要】：目的探讨类胚胎致死性异常视觉基因1(ELAV1)在卵巢浆液性肿瘤组织中的表达与卵巢浆液性癌化疗耐药及预后的关系。方法采用免疫组化法对2010年1月至2013年2月中国医科大学附属盛京医院收治的40例卵巢浆液性癌(化疗耐药20例和化疗敏感20例)、15例卵巢交界性浆液性瘤、20例卵巢良性浆液性瘤及15例正常卵巢组织中的ELAV1蛋白表达进行检测,并对ELAV1表达与患者临床病理资料及生存率的关系进行分析。结果 (1)ELAV1蛋白胞浆在卵巢浆液性癌中的阳性表达率明显高于卵巢交界性浆液性瘤、卵巢良性浆液性瘤和正常卵巢组织(P0.05),且在卵巢癌化疗耐药组织中明显高于化疗敏感组织(P0.05)。(2)ELAV1蛋白胞核阳性表达率在卵巢浆液性癌、卵巢交界性浆液性瘤、卵巢良性浆液性瘤及正常卵巢组织中差异无统计学意义(P0.05)。(3)胞浆ELAV1的表达与卵巢浆液性癌FIGO病理分期及淋巴结转移情况相关(P0.05),与患者年龄、是否绝经及分化程度无关(P0.05)。(4)Kaplan-Meier生存分析提示:ELAV1蛋白胞浆阳性和化疗耐药患者生存时间短。结论 ELAV1可能与卵巢浆液性癌的发生发展相关,可作为预测卵巢浆液性癌化疗耐药及预后的指标。
[Abstract]:Objective to investigate the relationship between the expression of ELAV1 in ovarian serous tumor and chemotherapeutic resistance and prognosis of ovarian serous carcinoma. Methods from January 2010 to February 2013, 40 cases of ovarian serous carcinoma (20 cases of chemotherapeutic resistance and 20 cases of chemosensitivity) were treated in Shengjing Hospital of China Medical University from January 2010 to February 2013. 15 cases of ovarian borderline serous tumor were treated with immunohistochemical method. The expression of ELAV1 protein was detected in benign serous tumor and 15 normal ovarian tissues. The relationship between ELAV1 expression and clinicopathological data and survival rate was analyzed. Results (1) the positive expression rate of ELAV1 protein in ovarian serous carcinoma was significantly higher than that in ovarian borderline serous tumor. The positive expression rate of ELAV1 protein in ovarian benign serous tumor and normal ovarian tissue (P0.05) was significantly higher than that in chemotherapy-resistant ovarian cancer (P0.05). (2) in ovarian serous carcinoma and borderline serous ovarian tumor. There was no significant difference between benign ovarian serous tumor and normal ovarian tissue (P0.05). (3) the expression of ELAV1 in cytoplasm was correlated with Figo pathological stage and lymph node metastasis of ovarian serous carcinoma (P0.05), and the expression of ELAV1 was correlated with the age of the patients. There was no correlation between menopause and differentiation (P0.05). (4) Kaplan-Meier survival analysis showed that the survival time of the patients with cytoplasmic positive and chemotherapeutic resistance was short. Conclusion ELAV1 may be related to the occurrence and development of ovarian serous carcinoma and can be used as a predictor of chemotherapeutic resistance and prognosis of ovarian serous carcinoma.
【作者单位】：中国医科大学附属盛京医院妇产科;
【分类号】：R737.31

【相似文献】